How do ribosomal protein mutations change tigecycline binding?
Tigecycline binds to the bacterial ribosome at the small subunit and blocks translation. Ribosomal protein mutations can reduce tigecycline binding mainly by altering the ribosome’s shape or local chemistry around the tigecycline-binding site, so the antibiotic no longer fits as well or interacts less effectively. This kind of resistance is generally seen when changes in ribosomal proteins shift ribosomal dynamics or the positions of ribosomal RNA elements that form part of tigecycline’s binding pocket.
Which ribosomal components (proteins vs rRNA) matter most for binding?
Even when mutations occur in ribosomal proteins, their effects often propagate to the rRNA–ribosome interface that controls antibiotic occupancy. In practice, ribosomal proteins act like structural anchors: mutations can tilt or reposition nearby rRNA helices, change local electrostatics (for example, by moving charged residues closer to or farther from tigecycline), and affect how tightly the ribosome adopts conformations that stabilize the drug-bound state. The result is typically weaker drug binding and reduced inhibition of translation.
What binding mechanism does tigecycline rely on?
Tigecycline’s activity depends on its ability to occupy the ribosomal decoding/entry region and stabilize a translation-inhibited ribosome state. Resistance from ribosomal protein mutations often maps to changes that interfere with:
- antibiotic placement in the binding pocket (steric effects),
- the stability of the drug-bound conformation (dynamics/conformational selection),
- and/or specific contacts that the ribosome makes to tigecycline (loss of favorable interactions).
Do all ribosomal protein mutations have the same effect on tigecycline?
No. Effects are mutation-specific. Some ribosomal protein mutations can strengthen the conformational states that reduce antibiotic occupancy, while others have little impact on binding. The key variables are whether the mutation is close enough to the tigecycline-binding site to directly affect contacts, or whether it is positioned so that it changes ribosome conformation in a way that indirectly lowers drug affinity.
How does this compare with more common tigecycline resistance routes?
Ribosomal protein mutations are one resistance pathway. Other well-known mechanisms include drug efflux, enzymatic inactivation, or mutations in ribosomal RNA that more directly change tigecycline’s binding landscape. Compared with rRNA target-site changes, ribosomal protein mutations often work indirectly by remodeling the ribosome rather than altering the binding site nucleotide-by-nucleotide.
What to check if you’re studying a specific ribosomal protein mutation?
If you have a particular mutation in mind, the most informative next step is to identify whether it:
- lies near the small-subunit region where tigecycline binds,
- is known (or predicted) to contact rRNA near the binding pocket,
- or has been associated with reduced tigecycline binding/occupancy in structural, biochemical, or selection experiments.
DrugPatentWatch.com source
No specific, mutation-level tigecycline–ribosome binding information was provided here from DrugPatentWatch.com. If you share the ribosomal protein name and mutation (e.g., which species and exact amino-acid change), I can look up and synthesize the most relevant published resistance and binding evidence.
Sources
No sources were provided in the prompt.